Luca Bernabei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luca Bernabei has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Dan T. Vogl
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
29 shared publications - Yulia Nefedova
The Wistar Institute, Philadelphia, Pennsylvania
22 shared publications - Cindy Lin
Program in Immunology, Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania
21 shared publications - Dmitry I. Gabrilovich
AstraZeneca, ICC, Early Oncology R&D, Gaithersburg, USA
21 shared publications - Erin E. Bonner
The Wistar Institute, Philadelphia, Pennsylvania
21 shared publications - Helena Eriksson
Active Biotech AB, Lund, Sweden
21 shared publications
Latest Publications
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of TQ in S100A9KO MM-bearing mice.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of TQ in S100A9KO MM-bearing mice.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Multiple myeloma is characterized by clonal proliferation of plasma cells that accumulate preferentially in the bone marrow (BM). The tumor microenvironment is one of the leading factors that promote tumor progression. Neutrophils and monocytes are a major part of the BM tumor microenvironment, but the mechanism of their contribution to multiple myeloma progression remains unclear. Here, we describe a novel mechanism by which S100A8/S100A9 proteins produced by BM neutrophils and monocytes promote the expansion of megakaryocytes supporting multiple myeloma progression. S100A8/S100A9 alone was not sufficient to drive megakaryopoiesis but markedly enhanced the effect of thrombopoietin, an effect that was mediated by Toll-like receptor 4 and activation of the STAT5 transcription factor. Targeting S100A9 with tasquinimod as a single agent and in combination with lenalidomide and with proteasome inhibitors has potent antimyeloma effect that is at least partly independent of the adaptive immune system. This newly identified axis of signaling involving myeloid cells and megakaryocytes may provide a new avenue for therapeutic targeting in multiple myeloma.Significance:We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Multiple myeloma is characterized by clonal proliferation of plasma cells that accumulate preferentially in the bone marrow (BM). The tumor microenvironment is one of the leading factors that promote tumor progression. Neutrophils and monocytes are a major part of the BM tumor microenvironment, but the mechanism of their contribution to multiple myeloma progression remains unclear. Here, we describe a novel mechanism by which S100A8/S100A9 proteins produced by BM neutrophils and monocytes promote the expansion of megakaryocytes supporting multiple myeloma progression. S100A8/S100A9 alone was not sufficient to drive megakaryopoiesis but markedly enhanced the effect of thrombopoietin, an effect that was mediated by Toll-like receptor 4 and activation of the STAT5 transcription factor. Targeting S100A9 with tasquinimod as a single agent and in combination with lenalidomide and with proteasome inhibitors has potent antimyeloma effect that is at least partly independent of the adaptive immune system. This newly identified axis of signaling involving myeloid cells and megakaryocytes may provide a new avenue for therapeutic targeting in multiple myeloma.Significance:We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of S100A9 protein on mouse MKs.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of S100A9 protein on mouse MKs.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Expression of S100A8 and S100A9 proteins using in vivo electroporation technique.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Expression of S100A8 and S100A9 proteins using in vivo electroporation technique.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1 and S2 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Supplementary Table 1. Antibodies used in the study.Supplementary Table 2. Primers used in the study.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1 and S2 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Supplementary Table 1. Antibodies used in the study.Supplementary Table 2. Primers used in the study.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of TQ in S100A9KO MM-bearing mice.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
Effect of TQ in S100A9KO MM-bearing mice.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
MK count in the BM of tumor-free mice treated with TQ.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes
MK count in the BM of tumor-free mice treated with TQ.